AXSM Q2 2023 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$47M+429.5% YoY

Gross Profit

$42M90.2% margin

Operating Income

-$65M-139.3% margin

Net Income

-$67M-143.8% margin

EPS (Diluted)

$-1.54

QoQ Revenue Growth

-50.6%

Cash Flow

Operating Cash Flow

-$55M

Free Cash Flow

-$55M

Stock-Based Comp.

$16M

Balance Sheet

Total Assets

$612M

Total Liabilities

$333M

Stockholders' Equity

$279M

Cash & Equivalents

$437M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$47M	$9M	+429.5%
Gross Profit	$42M	$8M	+437.2%
Operating Income	-$65M	-$39M	-66.0%
Net Income	-$67M	-$41M	-62.1%

Revenue Segments

Product

$46M99%

Royalty

$683,0001%